Demographic and clinical characteristics of the patients (n=3395)
| Variable | n (%) | |
| Sex | Male | 1870 (55.1) |
| Female | 1525 (44.9) | |
| Age (in years) | 15–25 | 1268 (37.3) |
| 26–35 | 1186 (34.9) | |
| 36–45 | 529 (15.6) | |
| ≥46 | 412 (12.1) | |
| Drug resistance type | Rifampin/Isoniazid(RIF/INH) status unknown | 1810 (53.3) |
| MDR-TB | 1585 (46.7) | |
| Anatomical site of TB | Pulmonary | 3171 (93.4) |
| Extra-pulmonary | 224 (6.6) | |
| Previous TB treatment | New | 462 (13.6) |
| Previously treated | 2933 (86.4) | |
| Previous exposure to SLDs | Yes | 1421 (41.9) |
| No | 1842 (54.3) | |
| Unknown | 132 (3.9) | |
| Drug resistance identification method | GeneXpert MTB/RIF | 1967 (57.9) |
| Culture/LPA | 1275 (37.6) | |
| Clinical | 153 (4.5) | |
| Diagnosis method | Bacteriological | 3242 (95.5) |
| Clinical | 153 (4.5) | |
| HIV infection | Not infected | 2554 (75.2) |
| Infected | 767 (22.6) | |
| Unknown | 74 (2.2) | |
| ART status | Not applicable | 2556 (75.3) |
| On ART | 686 (20.2) | |
| HIV status known but, ART status unknown | 79 (2.3) | |
| Both ART and HIV statuses unknown | 74 (2.2) | |
| Contact history of patient with MDR-TB | Yes | 204 (6.0) |
| No | 1511 (44.5) | |
| Unknown | 1680 (49.5) | |
| Hospitalisation history at treatment initiation | Hospitalised | 1831 (53.9) |
| Not hospitalised | 487 (14.3) | |
| Unknown | 1077 (31.7) | |
| Treatment interruption | Never interrupted/interruption status unknown | 3192 (94.0) |
| At least 1 day interrupted | 203 (6.0) |
ART, antiretroviral therapy; LPA, line probe assay; MDR, multidrug-resistant; SLDs, second-line drugs; TB, tuberculosis.